Solventum Q4 sales beat estimates

Solventum

26/02/2026 21:52

Overview

Healthcare solutions provider's Q4 sales beat analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Outlook

Solventum expects full-year 2026 organic sales growth of 2.0% to 3.0%

Company projects 2026 adjusted EPS between $6.40 and $6.60

Solventum anticipates free cash flow of ~$200 mln for 2026

Result Drivers

ORGANIC SALES GROWTH - Driven by strong performance in Infection Prevention and Surgical Solutions and Dental Solutions segments

DIVESTITURE IMPACT - Debt paydown from Purification and Filtration sale boosted adjusted EPS

Company press release: ID:nPn4mCZkBa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 sales
Beat
$2 bln
$1.96 bln (10 Analysts)
Q4 Adjusted EPS
Beat
$1.57
$1.50 (11 Analysts)
Q4 EPS
$0.36
Q4 Net Income
$63 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Solventum Corp is $97.00, about 29.2% above its February 25 closing price of $75.08

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)